Phosphodiesterase Inhibitors Could Reverse the Proliferation of BPH Epithelial Cells Induced by CD8+ T Cells in Low Androgen Condition

April 2018 in “ The Journal of Urology ”

Song Jin, Yang Yang, Shuai Hu, Jindong Sheng, Peng Xiang, Jing Peng, Jie Jin

New to Finasteride? There is a guide in the encyclopedia. Read the guide →

phosphodiesterase inhibitors PDE5Is tadalafil benign prostatic hyperplasia BPH CD8+ T cells low androgen condition cGMP/PKG signaling pathway finasteride 5α-reductase inhibitors PDE5 protein CCL5 BPH-1 cells Cialis Propecia

Studysummary This study found that phosphodiesterase inhibitors may suppress the proliferation of benign prostatic hyperplasia epithelial cells by modulating CCL5 levels in low androgen conditions.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on auajournals.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.

March 2014 in “The Journal of Urology”

In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.

research Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

1 citations , December 2023 in “Curēus”

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?

April 2022

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “Figshare”

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

research Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]

January 2015 in “Faculty of 1000 Research Ltd”

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.